An Introduction to Dermatological Conditions
Autoimmunity and deregulation of the immune system contribute to many skin diseases including systemic sclerosis, dermatomyositis, psoriasis, vitiligo, alopecia areata and lichen sclerosus; as well as inflammatory diseases such as hidradenitis suppurativa, allergic contact dermatitis and atopic eczema; and also autoimmune blistering diseases, including pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Established treatments include systemic corticosteroids and immunosuppressive therapies, while new therapies in development include biologic therapies targeting cytokines such as tumour necrosis factor alpha (TNF-alpha) and interleukins IL-23 and IL-17; enzymes such as Janus kinase-1 (JAK-1); and the regulatory proteinretinoic acid receptor-related-orphan-receptor-gamma t (RORγt).
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Dermatological Conditions Content
Sonja Ständer, EADV 2021: New Therapies for Chronic Pruritus and Prurigo
touchIMMUNOLOGY had the great pleasure of speaking with Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) about new treatments for chronic pruritus and prurigo. Her presentation entitled ‘New treatments for chronic pruritus and prurigo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Disclosures: Prof. Sonja Ständer has acted as an investigator […]
Sonja Ständer, EADV 2021: Nemolizumab in the Treatment of Prurigo Nodularis
Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) kindly took the time to speak to us about the health burden of prurigo and recent investigations into the IL-31 targeted therapy, nemolizumab. Her presentation entitled ‘Nemolizumab rapidly relieves itch and sleep disturbances in patients with prurigo nodularis’ was given at the EADV 30th Congress, 29 Sep […]
Sorena Kiani, EAACI 2021: Berotralstat in the Treatment of Hereditary Angioedema
touchIMMUNOLOGY joins Dr Sorena Kiani (Barts Health NHS Trust, London, UK) to discuss the efficacy and safety of berotralstat in the treatment of hereditary angioedema. Questions 1. What are the unmet needs in the treatment of hereditary angioedema (HAE)? (00:17-01:53) 2. What is berotralstat and what is the rationale for its use in HAE? (01:53-03:17) […]
Marcus Maurer, EAACI 2021: Avapritinib for Advanced Systemic Mastocytosis – The PATHFINDER Study
touchIMMUNOLOGY joins Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the rationale behind avapritinib for advanced systemic mastocytosis and the results of the PATHFINDER study. Questions Could you give us a brief overview of the disease burden of advanced systemic mastocytosis and the unmet needs in its treatment? (0:26) […]
Marcus Maurer, EAACI 2021: CDX-0159 for the Treatment of Urticaria
touchIMMUNOLOGY were delighted to talk with Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the Phase 1a study of CDX-0159 in patients with chronic inducible urticaria. Questions What is CDX-0159 and what is the rationale for its use in patients with chronic inducible urticaria? (0:26) Could you tell us […]
Esther van Zuuren, EADV 2021: Topical Therapies in Rosacea
It was a pleasure to speak with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) about current and emerging topical therapies in rosacea. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you give us an overview of the current […]
Esther van Zuuren, EADV 2021: Rosacea Classification
It was a pleasure to be able to catch up with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) to discuss rosacea classification and how this can impact treatment choices. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you […]
Dedee Murrell, AAD VMX 2021: BELIEVE Phase 2 Study of Rilzabrutinib in Pemphigus
It was a pleasure to be able to speak with Prof. Dedee Murrell (St George Hospital, University of New South Wales, Sydney, Australia) about the BELIEVE Phase 2 (Part A) Study (NCT02704429) which investigated the oral BTK inhibitor, rilzabrutinib, in pemphigus. Her abstract entitled ‘Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid […]
Jonathan Bernstein, AAAAI 2021: Final results from the HELP Study
touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the findings from the HELP study, investigating lanadelumab for the prevention of hereditary angioedema (HAE) attacks. The abstract ‘Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!